Sanofi (SNY) Tops Q4 EPS by 74c; offers FY24 guidance

Sanofi (NASDAQ: SNY) reported Q4 EPS of EUR1.66, EUR0.74 better than the analyst estimate of EUR0.92. Revenue for the quarter came in at EUR10.92 billion versus the consensus estimate of EUR12.65 billion.

GUIDANCE

Sanofi expects 2024 business EPS(1) to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit(2) at CER including the higher expected tax rate, barring unforeseen major adverse events. Applying average January 2024 exchange rates, the currency impact on 2024 business EPS is estimated between -3.5% to -4.5%.

For earnings history and earnings-related data on Sanofi (SNY) click here.

You May Also Be Interested In

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
• Sanofi (SNY) call put ratio 8.4 calls to 1 put with a focus on July 45 calls
• Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D